Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burge, M. R.
Right arrow Articles by Schade, D. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burge, M. R.
Right arrow Articles by Schade, D. S.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes Care, Vol 20, Issue 2 152-155, Copyright © 1997 by American Diabetes Association


ARTICLES

Meal composition is a determinant of lispro-induced hypoglycemia in IDDM

MR Burge, KR Castillo and DS Schade
University of New Mexico Health Sciences Center, Department of Medicine/Endocrinology, Albuquerque 87131, USA.

OBJECTIVE: Lispro is a newly FDA-approved analog of human insulin that will be widely used in patients with IDDM. This insulin, however, may have an increased potential for hypoglycemia because of its very rapid subcutaneous absorption, especially in a setting of decreased carbohydrate intake. Using a short-term prospective randomized parallel group-study design, we studied the incidence of hypoglycemia when lispro was given before breakfast compared with regular human insulin. Since carbohydrate intake is a determinant of postprandial glycemia, we administered three isocaloric meals characterized by low, average, and high carbohydrate content. RESEARCH DESIGN AND METHODS: Two groups of six IDDM subjects were randomized to receive 0.15 U/kg of lispro or regular human insulin subcutaneously before the ingestion of three 500-kcal breakfast meals of differing carbohydrate content on separate days. Lispro was administered at mealtime, and regular insulin was administered 30 min before mealtime. RESULTS: Postprandial plasma glucose concentrations were decreased in the lispro group compared with the regular-insulin group for all three meal types (P < 0.05), and hypoglycemia developed more frequently and rapidly in the lispro group, compared with the regular-insulin group by survival analysis. Additionally, peak insulin concentrations were higher (P < 0.001) and peaked more rapidly (P < 0.05) in the lispro group, compared with the regular-insulin group. CONCLUSIONS: We conclude that lispro has a tendency for early postprandial hypoglycemia compared with regular insulin in the setting of reduced carbohydrate intake. This fact should be told to patients who decide to switch from regular insulin to lispro. Health care professionals should instruct their IDDM patients to monitor glucose levels frequently after switching to lispro since adjustments in their carbohydrate intake and/or their lispro dosage may be necessary to avoid hypoglycemia.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
NEJMHome page
I. B. Hirsch
Insulin Analogues
N. Engl. J. Med., January 13, 2005; 352(2): 174 - 183.
[Full Text] [PDF]


Home page
DiabetesHome page
F. Porcellati, S. Pampanelli, P. Rossetti, C. Cordoni, S. Marzotti, L. Scionti, G. B. Bolli, and C. G. Fanelli
Counterregulatory Hormone and Symptom Responses to Insulin-Induced Hypoglycemia in the Postprandial State in Humans
Diabetes, November 1, 2003; 52(11): 2774 - 2783.
[Abstract] [Full Text] [PDF]


Home page
DTBHome page
{blacktriangledown}Humalog - a new insulin analogue
DTB, August 1, 1997; 35(8): 57 - 58.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. R. Burge, D. L. Waters, J. H. Holcombe, and D. S. Schade
Prolonged Efficacy of Short Acting Insulin Lispro in Combination with Human Ultralente in Insulin-Dependent Diabetes Mellitus
J. Clin. Endocrinol. Metab., March 1, 1997; 82(3): 920 - 924.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1997 by the American Diabetes Association.